Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis

Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis The Danaher Beacon for Brain Injury Diagnostics seeks to identify mild Traumatic Brain Injury (TBI) earlier and more precisely. Scientists will evaluate new blood-based biomarkers using highly sensitive technology from Beckman Coulter Diagnostics. This approach could potentially be adapted for diagnosis of other... Read more

Danaher Launches Collaboration with Cincinnati Children's Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development

Danaher Launches Collaboration with Cincinnati Children’s Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development Danaher Beacon for Preclinical Drug Safety seeks to address major cause of failure in clinical trials Program will leverage automated liver organoid technology for drug toxicity screening Aims to expand genetic diversity of screening, accelerate therapy development,... Read more

Biognosys Expands US Footprint with New Proteomics CRO Facility in Massachusetts

The new CRO facility for proteomics services in Newton, Massachusetts ensures closer proximity to US customers Biognosys’ center of excellence for proteomics innovation at its headquarters near Zurich, Switzerland continues to offer its entire portfolio of services for discovery, targeted, and structural proteomics for all regions, including the Americas ZURICH & NEWTON, Massachusetts–(BUSINESS WIRE)– Biognosys,... Read more

New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma

Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2 New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6 Basel, 11 December 2023 – Roche (SIX: RO, ROG;... Read more

New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A

Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth 1 At nearly two years median follow-up in the descriptive, single-arm study, no babies experienced spontaneous bleeds requiring treatment, and all treated bleeds were as a result of... Read more

Combining a Small Instrument Size with the Highest Levels of Sensitivity in Their Class, and Featuring a Model Suitable for High-Temperature/High-Humidity RegionsNew Compact IRSpirit-X Series Fourier Transform Infrared Spectrophotometers

Combining a Small Instrument Size with the Highest Levels of Sensitivity in Their Class, and Featuring a Model Suitable for High-Temperature/High-Humidity RegionsNew Compact IRSpirit-X Series Fourier Transform Infrared Spectrophotometers Read more